Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Swiss drugmaker Vifor had bid interest but talks halted - sources

11/27/2020 | 09:27am EST
FILE PHOTO: The logo of Swiss drugmaker Vifor Pharma in Glattbrugg

LONDON/ZURICH (Reuters) - Swiss drugmaker Vifor Pharma had a recent takeover approach from at least one private equity firm, but talks were halted due to differences over price, two sources familiar with the situation said.

The financial investors behind the initial approach suspended the discussions after failing to agree on a deal that would have seen Vifor delisted from Switzerland's SIX exchange, the sources told Reuters on condition of anonymity.

Vifor declined to comment on Friday.

Shares in Vifor jumped 17% to 139.35 Swiss francs by 1303 GMT after Reuters was first to report the takeover talks.

Reuters was not immediately able to determine the names of the interested parties in Vifor, which at a price of 123 Swiss francs per share, is valued at around 8 billion Swiss francs ($8.82 billion).

The proposed takeover would have valued Vifor at about 10 billion Swiss francs, one of the sources said.

It was not immediately clear whether negotiations would be resumed or whether other bidders including healthcare companies might also consider making an approach for Vifor.

Investor Martin Ebner and his wife Rosmarie are Vifor's largest shareholders with a combined stake of around 20%, so any takeover is unlikely to succeed without their approval.

A spokesman for Ebner declined to comment.

Sources familiar with the situation said the Ebners could sell their stake under certain conditions.

Etienne Jornod, who led Vifor as chairman for more than two decades, resigned in May.

Vifor was listed in 2017 as part of the break up of Swiss drugmaker Galenica. Its main business is making active ingredients for iron deficiency such as Ferinject.

Vifor sold its immunotherapeutics subsidiary OM Pharma to Jornod's Optimus Holding for 435 million francs in September.

The deal, which helped streamline Vifor's portfolio, made the company a more attractive target, financial sources have said.

The company's revenues rose by 18.5% in 2019 to 1.88 billion Swiss francs and it reported a profit of 159 million francs. For the current year, it has forecast growth will slow to 5% in local currencies.

Vifor also operates a joint venture with Fresenius Medical Care, which develops and markets drugs for kidney disease. Its smallest business is a drug against elevated potassium levels.

($1 = 0.9074 Swiss francs)

(Reporting by Pamela Barbaglia, Oliver Hirt and Arno Schuetze; Writing by Michael Shields; Editing by Alexander Smith and Susan Fenton)

By Pamela Barbaglia, Oliver Hirt and Arno Schuetze


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.67% 69.22 Delayed Quote.0.82%
FRESENIUS SE & CO. KGAA -0.08% 38.18 Delayed Quote.0.98%
GALENICA AG 0.75% 60.45 Delayed Quote.1.69%
VIFOR PHARMA -7.58% 125.05 Delayed Quote.-2.66%
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
11:16aEuropean ADRs Move Lower in Friday Trading
MT
01/19Cytosorbents' CytoSorb Blood Purification Technology Gets Nod from South Kore..
MT
01/18FMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs maintains a Buy rating
MD
01/18FRESENIUS SE : Goldman Sachs maintains a Buy rating
MD
01/13FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from JP Morgan
MD
01/12FRESENIUS SE : Buy rating from JP Morgan
MD
01/11FRESENIUS MEDICAL CARE : Frenova enrolls patients in initiative to build world's..
PU
01/11FRESENIUS SE : Jefferies remains a Sell rating
MD
01/11FMC FRESENIUS MEDICAL CARE AG & CO K : Downgraded from Neutral to Sell by Jeffer..
MD
01/07European ADRs Move Higher in Thursday Trading
MT
More news
Financials (USD)
Sales 2020 21 457 M - -
Net income 2020 1 551 M - -
Net Debt 2020 14 728 M - -
P/E ratio 2020 16,0x
Yield 2020 1,72%
Capitalization 24 497 M 24 457 M -
EV / Sales 2020 1,83x
EV / Sales 2021 1,72x
Nbr of Employees 126 463
Free-Float 63,7%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 95,98 $
Last Close Price 83,65 $
Spread / Highest target 34,0%
Spread / Average Target 14,7%
Spread / Lowest Target -22,4%
EPS Revisions
Managers and Directors
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer